Alligator Bioscience's Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology [Yahoo! Finance]
Aptevo Therapeutics Inc. (APVO)
Last aptevo therapeutics inc. earnings: 8/9 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aptevotherapeutics.com/investor-overview
Company Research
Source: Yahoo! Finance
The study reported Objective Response Rate (ORR) of 40.4% in 57 evaluable patients, primary endpoint was met. The novel combination of mitazalimab and mFOLFIRINOX and the unique dosing schedule resulted in an unprecedented Duration of Response (DoR, median 12.5 months) together with a prolonged Overall Survival (OS, median 14.3 months). These results compare favorably to the historically reported outcomes for FOLFIRINOX alone and most other standard of care or investigational therapies. These data were also presented at the ASCO annual meeting on June 1; updated data with longer follow-up are expected end of June 2024. Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the publication of positive Phase 2 data on its lead drug candidate mitazalimab in first line metastatic pancreatic cancer in The Lancet Oncology . The journal is an internationally trusted source of clinical, and global health knowledge. With an Impact Factor of 51.1, it is the world
Show less
Read more
Impact Snapshot
Event Time:
APVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APVO alerts
High impacting Aptevo Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
APVO
News
- Alligator Bioscience Announces Substantial Overall Survival Benefit and Unprecedented Duration of Response in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer [Yahoo! Finance]Yahoo! Finance
- Alligator Bioscience Announces Financing of Up to SEK 80 Million Extending Cash Runway to Q1 2025 [Yahoo! Finance]Yahoo! Finance
- Aptevo Participating in the BIO International ConventionAccesswire
- Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA [Yahoo! Finance]Yahoo! Finance
APVO
Sec Filings
- 6/26/24 - Form S-1/A
- 6/14/24 - Form S-1
- 6/10/24 - Form 8-K
- APVO's page on the SEC website